There has been a dramatic increase in the life expectancy of patients with cystic fibrosis (CF) over the last 20 years. CF used to be fatal in childhood but now, over a third of the patients are adults. The reasons for improved survival are multi-factorial. The disease affects most systems of the body although the majority of morbidity and mortality is due to lung disease. As in any life-threatening disease, in addition to medical issues, there are many psychosocial and spiritual issues, which need attention. Transition from paediatric to adult care needs to be handled very sensitively. Arranging a balanced and reliable system of care – out-patient, in-patient and home care – is essential to ensure the patient’s survival and quality of life is as good as possible.

Keywords:
Cystic fibrosis
1.
Andersen DH: Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathological study. Am J Dis Child 1938;56:344–399.
2.
Dodge JV, Morison S, Lewis PA, et al: Incidence, population and survival of cystic fibrosis in the UK (1968–95). Arch Dis Child 1997; 77:493–496.
3.
Cystic Fibrosis Foundation Patients Registry: 1995 Annual Data Report, Bethesda, 1996.
4.
Elborn JS, Shale DJ, Britton JR: Cystic fibrosis: Current survival and population estimates to the year 2000. Thorax 1991;46:881–885.
5.
Cystic Fibrosis Foundation Patient Registry: 1998 Annual Data Report, Bethesda, 1999.
6.
Gan KH, Gens WP, Bakker W, Lamers CB, Heijerman HG: Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years. Thorax 1995;50:1301–1304.
7.
Girod S, Galabert C, Lecure A, Zahm JM, Puchelle E: Phospholipid composition and surface active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Paediatr Pulmonol 1992;13:22–27.
8.
Kraemer R: Early detection of lung disease. Respiration, in press.
9.
Ryland D, Reid L: The pulmonary circulation in cystic fibrosis. Thorax 1975;30:285–292.
10.
Penketh AR, Wise A, Mearns MB, Hodson ME, Batten JC: Cystic fibrosis in adolescents and adults. Thorax 1987;42:526–532.
11.
Tablan OC, Martone WJ, Doershuk CF, et al: Colonisation of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest 1987;91:527–532.
12.
Thomas SR, Gyi KM, Gaya H, Hodson ME: Methicillin-resistant Staphylococcus aureus: Impact at a national cystic fibrosis centre. J Hosp Infect 1998;40:203–209.
13.
Efthimiou J, Hodson ME, Taylor P, Taylor AJ, Batten JC: Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis. Thorax 1984;39:150–154.
14.
Govan JRW, Nelson JW: Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992;48:912–930.
15.
Santis G, Hodson ME, Strickland B: High resolution computed tomography in adult cystic fibrosis patients with mild lung disease. Clinical Radiology 1991;44:20–22.
16.
Ronchetti R, Stocks J, Freedman N, Glass H, Godfrey S: Clinical application of regional lung function studies in infants and small children using 13N. Arch Dis Child 1975;50:595–603.
17.
Gilljam H, Stenlund C, Ericsson-Hollsing A, Strandvik B: Passive smoking in cystic fibrosis. Respir Med 1990;84:289–291.
18.
Pryor JA, Webber BA: Physiotherapy in cystic fibrosis – which technique? Physiotherapy 1992;78:105–108.
19.
Campbell IA, Jenkins J, Prescott RJ: Intermittent ciprofloxacin in adults with cystic fibrosis and chronic pseudomonas pulmonary infection. Med Sci Res 1989;17:797–798.
20.
Szaff M, Hoiby N, Flensborg EW: Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651–657.
21.
Cystic Fibrosis Foundation: Consensus Conferences – Concepts in Care. Bethesda, Cystic Fibrosis Foundation, 1994, vol 5, section 1.
22.
Stead RJ, Davidson TI, Duncan FR, Hodson ME, Batten JC: Use of a totally implantable system for venous access in cystic fibrosis. Thorax 1987;42:149–150.
23.
Hodson ME: Respiratory system; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 10b.
24.
Touw DJ, Brimicombe RW, Hodson ME, Heijermen HGM, Bakker W: Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594–1604.
25.
Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE: Nebulised antipseudomonal antibiotics therapy in cystic fibrosis: A meta-analysis of benefits and risks. Thorax 1996;51:364–368.
26.
Ramsey BE, Pepe MS, Quan JM, et al: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23–30.
27.
Maddison J, Dodd M, Webb AK: Nebulised colistin causes chest tightness in adults with cystic fibrosis. Respir Med 1994;88:145–147.
28.
Eng PA, Morton J, Douglas JA, Riedler J, Wilson J, Robertson CF: Short-term efficacy of ultrasonically nebulised hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77–83.
29.
Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al: Effect of aerosolised recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637–642.
30.
Shah PL, Scott SF, Geddes DM, Hodson ME: Two years experience with recombinant human Dnase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995;89:499–502.
31.
Madden BM: Lung transplantation; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 18.
32.
Starnes VA, Barr M, Cohen R, et al: Living donor lobar lung transplantation experience: Intermediate results. J Thorac Cardiovasc Surg 1996;112:1284–1291.
33.
Zeitlin PL: Future pharmacological treatment of cystic fibrosis. Respiration, in press.
34.
Penketh AR, Knight RK, Hodson ME, Batten JC: Management of pneumothorax in adults. Thorax 1982;37:850–853.
35.
Sweezey NB, Fellows KE: Bronchial artery embolisation for severe haemoptysis in cystic fibrosis. Chest 1990;97:1322–1326.
36.
Hiller EJ: Pathogenesis and management of aspergillosis in cystic fibrosis. Arch Dis Child 1990;65:397–398.
37.
Stern RC, Borkat G, Hirschfeld SS, et al: Heart failure in cystic fibrosis. Treatment and prognosis of cor pulmonale with failure of the right side of the heart. Am J Dis Child 1980;134:267–272.
38.
Hodson ME, Madden BP, Steven MH, Tsang VT, Yacoub MH: Non-invasive mechanical ventilation for cystic fibrosis patients – a potential bridge to transplantation. Eur Respir J 1991;4:524–527.
39.
Davidson AGF: Gastrointestinal and pancreatic diseases in cystic fibrosis; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 12.
40.
Poole S, McAlweenie A, Ashworth F: Dietary treatment of cystic fibrosis; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, pp 384–395.
41.
Westaby D: Liver and biliary disease in cystic fibrosis; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 13.
42.
Koch C, Lanng S: Other organ systems; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 19a.
43.
Yung DM, Hodson ME: Diabetes in cystic fibrosis. J R Soc Med 1999;92(suppl 37):35–40.
44.
Elkin S: Osteoporosis; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 19b.
45.
Hodson ME: Vasculitis and arthropathy in cystic fibrosis. J R Soc Med 1999;85(suppl 9):38–40.
46.
Walters S, Britton J, Hodson ME: Demographic and social characteristics of adults with cystic fibrosis in the United Kingdon. Br Med J 1993;306:549–552.
47.
Sawyer SM: Reproductive and sexual health; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 14.
48.
Saunders C (ed): The Management of Terminal Disease. London, Arnold, 1978.
49.
Royal College of Physicians: Cystic fibrosis in adults. Recommendations for care of patients in the UK. Royal College of Physicians, London, 1990.
50.
Kuzemko JA: Home treatment of pulmonary infection in cystic fibrosis. Chest 1988;94(suppl 2):162–166.
51.
Duncan-Skingle F, Bramwell E: Cystic fibrosis home care; in Hodson ME, Geddes DM (eds): Cystic Fibrosis, ed 2. London, Arnold, 2000, chapt 19d.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.